Should we now adopt the HIV-RNA < 50 copy endpoint for clinical trials of antiretroviral-experienced as well as naive patients?

AIDS. 2007 Jul 31;21(12):1651-3. doi: 10.1097/QAD.0b013e3282703593.

Abstract

In the TORO, RESIST and POWER trials, the HIV-RNA < 50 copy endpoint showed the strongest durability over time, whereas HIV-RNA reductions of more than 1 log10 or below 400 copies/ml were less sustained during 48 weeks of treatment. Clinical trials of new antiretroviral drugs in highly experienced patients also show high rates of HIV-RNA suppression below 50 copies/ml. HIV-RNA suppression below 50 copies/ml should now become the standard efficacy endpoint across trials of both naive and experienced patients.

MeSH terms

  • Adult
  • Anti-HIV Agents / therapeutic use*
  • Antiretroviral Therapy, Highly Active
  • Female
  • HIV Infections / drug therapy*
  • HIV Infections / virology*
  • HIV-1 / isolation & purification*
  • Humans
  • Male
  • Middle Aged
  • RNA, Viral / blood
  • Randomized Controlled Trials as Topic / methods
  • Research Design
  • Treatment Outcome
  • Viral Load

Substances

  • Anti-HIV Agents
  • RNA, Viral